Prevents the marginal accumulation of neutrophils, reduces inflammatory exudation and the production of lymphokines, inhibits the migration of macrophages, reduces the intensity of infiltration and granulation processes, has local anti-inflammatory, antipruritic, antiallergic antiexudative effects.


Clobetasol propionate BP 0.05% w/w.

  • psoriasis (except for widespread plaque psoriasis);
  • eczema (refractory forms);
  • lichen planus;
  • discoid lupus erythematosus;
  • other skin diseases resistant to therapy with less active glucocorticoids;
  • skin diseases resistant to therapy with less active corticosteroids for external use.

Kredaveyt ointment is recommended for use in cases of skin lesions accompanied by dryness, hyperkeratosis, and thickening, since the ointment base of the drug helps retain moisture in the skin, and the cream is recommended for use in processes accompanied by weeping and severe inflammation.

The ointment is applied in a thin layer to the affected skin once or twice a day until the effect is achieved. Treatment should not be continued for more than 4 weeks without assessing the need for continuation. To treat exacerbations of skin diseases, repeated short courses of Kredaveyt can be administered. If continued therapy with glucocorticosteroids is necessary, less active drugs should be used.
In particularly resistant cases, especially in the presence of hyperkeratosis, the anti-inflammatory effect of Kredaveyt ointment can be enhanced by applying a polyethylene film bandage to the area of application at night, which is usually accompanied by a positive effect. In the future, the achieved effect can be maintained without the use of an occlusive dressing.